Alnylam Pharmaceuticals, Inc

About Alnylam Pharmaceuticals, Inc

Alnylam is the world’s leading RNA interference (RNAi) company.
Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality by harnessing the power of RNAi for human health as an innovative new class of medicines. We are a growing biopharmaceutical company with three approved medicines and a robust pipeline of investigational medicines focused in four strategic therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases, including several in late-stage development.
Headquartered in Cambridge, Mass., Alnylam employs over 1,500 people in 19 countries and is rapidly growing globally, with additional offices in Norton, Mass., Maidenhead, U.K., Zug, Switzerland, Amsterdam, Netherlands, and Tokyo, Japan. Alnylam is proud to have been recognized as one of The Boston Globe’s Top Places to Work six years in a row (2015-2020), a Great Place to Work in the U.K. and Switzerland two years in a row (2019-2020) and a Science Magazine’s Top Employer two years in a row (2019-2020). Please visit for more information.


Medical Affairs

May 2018 - August 2018 Cambridge, MA
“Reading literature ”

process chemistry intern

June 2018 - August 2018 Cambridge, MA
“Worked with many smart people from whom I learned a lot by watching and asking questions. Going to meetings I also learned a lot about the nature of the industry in addition to the science. I worked on a hands on project that I could work independently and ask questions and receive guidance as well as step by step instructions on how to achieve the goal. ”
See All